PMD Alliance | Strategic Alliance Partners

The movement disorder specialist and patient living with Parkinson disease highlighted the need for a more human-centered approach in managing chronic and progressive movement disorders. [WATCH TIME: 6 minutes]

The neuropsychiatry researcher at King's College London highlighted significant gender differences in anxiety, depression, quality of life, and social support among patients with PD undergoing deep brain stimulation. [WATCH TIME: 5 minutes]

The assistant professor of medicine at Stanford University highlighted how gastrointestinal dysfunction in Parkinson disease can affect levodopa bioavailability and symptom management. [WATCH TIME: 7 minutes]

Laren Becker, MD, PhD, a physician-scientist at Stanford University, discussed how gastrointestinal dysfunction and peripheral dopaminergic activity impact Parkinson disease treatment and progression.

Continuous subcutaneous apomorphine infusion significantly reduces OFF episodes and enhances ON time in Parkinson's disease patients, improving overall health status.

The neurologist at Christiana Care discussed how focused ultrasound may be emerging as a preferred, less invasive treatment option for essential tremor, especially in older patients with comorbidities. [WATCH TIME: 5 minutes]

The director of the Movement Disorders Clinic at Houston Methodist Hospital discussed the distinct features, progression, and clinical implications of psychosis in Parkinson disease. [WATCH TIME: 4 minutes]

The movement disorder neurologist at University of Rochester Medical Center outlined a 5-pillar model that emphasized holistic care, patient-centered communication, and proactive support in movement disorders. [WATCH TIME: 5 minutes]

The professor of psychology at Avila University discussed how cognitive behavioral therapy and social support can help to improve quality of life for individuals with Parkinson disease. [WATCH TIME: 4 minutes]

The chief program officer at PMD Alliance discussed the value of combining experiential learning and holistic care strategies to support advanced therapeutics in Parkinson disease. [WATCH TIME: 4 minutes]

Daniel Irizarry, MD, a former physician and patient living with PD, discussed how hands-on simulation training could enhance clinician empathy and improve treatment strategies.

Cynthia Fox, PhD, CCC-SLP, CEO and co-founder of LSVT Global, discussed the evolution of rehabilitative therapies in PD and stressed early referrals for speech, physical, and occupational therapy.

The medical advisor at Tactical Medical Solutions shared insights from both clinical and personal perspectives on the importance of empathy and active listening in managing Parkinson disease. [WATCH TIME: 3 minutes]

Jean Hubble, MD, a retired movement disorder specialist and consultant to the PMD Alliance, shares her reflections on National Women Physicians Day, the unique contributions of women in neurology, and the pathways to fostering future leaders in movement disorders care.

The executive director of the Association of Movement Disorder Advanced Practice Providers talked about a recent survey highlighting why patients with movement disorders may withhold critical health information from their providers.

The executive director of the Association of Movement Disorder Advanced Practice Providers discussed how effective patient care in movement disorders can lead to better management and treatment outcomes. [WATCH TIME: 4 minutes]

Approximately 83% of patients reported that they did not disclose to their provider that they experienced symptoms or had concerns about living with a movement disorder.

As part of our monthly clinician spotlight, NeurologyLive® highlighted movement disorder expert Kelly Papesh, DNP, APRN, FNP-BC, executive director of the Association of Movement Disorder Advanced Practice Providers.

In collaboration with Robert A. Hauser, MD, MBA, the survey aims to understand the impact of tremors in patients with Parkinson disease.

The clinical director of Parkinson & Movement Disorder Alliance shared her thoughts on potential therapies to increase management care options for patients with Parkinson disease. [WATCH TIME: 5 minutes]

The chief executive officer at Parkinson & Movement Disorder Alliance and the president at PD Avengers discussed the importance of awareness in movement disorders and the challenges that patients still face in getting access to treatments for improved quality of life. [WATCH TIME: 12 minutes

The professor of neurology and residency program director at MedStar Georgetown University Hospital spoke to the evolution of the utility of botulinumtoxins in the treatment of patients with Parkinson and other movement disorders. [WATCH TIME: 4 minutes]

Clinicians must be armed with fact-based information on all treatment options especially newer medications and technologies—good clinical care must be both patient-centric and knowledge-driven.

Robert A. Hauser, MD, MBA, director of the Parkinson’s and Movement Disorders Center at the University of South Florida, provided insight on the therapeutic potential of IPX203, and why it adds flexibility to the treatment of Parkinson disease.

The nurse practitioner at the University of Southern California Keck Medical School provided insight on steps before deep brain stimulation and how they can impact outcomes for patients with Parkinson disease. [WATCH TIME: 4 minutes]

Pooled results of a post hoc analysis from phase 3 studies of amantadine (Gocovri; Supernus) suggest that the therapy offers increased good ON time, and in intervals that are more predictable for patients, compared with placebo.

The assistant professor of neurology and director of the Movement Disorders Outreach Program at Mount Sinai Medical Center shed some light on the use of DBS in the clinic and how it has evolved as a therapeutic option for patients with Parkinson disease. [WATCH TIME: 2 minutes]